J. Gong, A. Chehrazi-raffle, and S. Reddi, Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations, J Immunother Cancer, vol.6, issue.1, p.8, 2018.

O. S. Qureshi, Y. Zheng, and K. Nakamura, Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4, Science, vol.332, issue.6029, pp.600-603, 2011.

L. E. Marengere, P. Waterhouse, and G. S. Duncan, Regulation of T cell receptor signaling by tyrosine phosphatase SYP association with CTLA-4, Science, vol.272, issue.5265, pp.1170-1173, 1996.

M. Martin, H. Schneider, and A. Azouz, , vol.4, p.28

, modulate cell surface raft expression in their regulation of T cell function, J Exp Med, vol.194, issue.11, pp.1675-1681, 2001.

C. P. Perez, N. Patel, and C. R. Mardis, Belatacept in solid organ transplant: review of current literature across transplant types, Transplantation, vol.102, issue.9, pp.1440-1452, 2018.

G. N. De-graav, C. C. Baan, and M. C. Clahsen-van-groningen, A randomized controlled clinical trial comparing belatacept with tacrolimus after de novo kidney transplantation

S. M. Krummey, T. L. Floyd, and D. Liu, Candida-elicited murine Th17 cells express high Ctla-4 compared with Th1 cells and are resistant to costimulation blockade, J Immunol, vol.192, issue.5, pp.2495-2504, 2014.
DOI : 10.4049/jimmunol.1301332
URL : http://www.jimmunol.org/content/192/5/2495.full.pdf

N. Poirier, A. M. Azimzadeh, and T. Zhang, Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation
DOI : 10.1126/scitranslmed.3000116
URL : http://europepmc.org/articles/pmc2860737?pdf=render

, Sci Transl Med, vol.2, issue.17, pp.17-27, 2010.

N. Dilek, N. Poirier, and P. Hulin, CTLA-4 and PD-L1 costimulation differentially controls immune synapses and function of human regulatory and conventional T-cells, PLoS One, vol.28, issue.12, p.83139, 2013.
DOI : 10.1371/journal.pone.0083139
URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0083139&type=printable

L. M. Charbonnier, B. Vokaer, and P. H. Lemaître, CTLA4-Ig restores rejection of MHC class-II mismatched allografts by disabling IL-2-expanded regulatory T cells, Am J Transplant, vol.12, issue.9, pp.2313-2321, 2012.
DOI : 10.1111/j.1600-6143.2012.04184.x
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-6143.2012.04184.x

I. Vogel, A. Kasran, and J. Cremer, CD28/CTLA-4/B7 costimulatory pathway blockade affects regulatory T-cell function in autoimmunity, Eur J Immunol, vol.45, issue.6, pp.1832-1841, 2015.
DOI : 10.1002/eji.201445190

M. Zaitsu, F. Issa, and J. Hester, Selective blockade of CD28 on human T cells facilitates regulation of alloimmune responses, JCI Insight, vol.2, p.89381, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02154998

B. Vanhove, G. Laflamme, and F. Coulon, Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody, Blood, vol.102, issue.2, pp.564-570, 2003.

S. J. Suchard, P. M. Davis, and S. Kansal, A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety, J Immunol, vol.191, issue.9, pp.4599-4610, 2013.
DOI : 10.4049/jimmunol.1300470
URL : http://www.jimmunol.org/content/191/9/4599.full.pdf

B. Vanhove, N. Poirier, and F. Fakhouri, Antagonist anti-CD28 therapeutics for the treatment of autoimmune disorders, Antibodies, vol.6, issue.4, p.19, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01885571

C. Mary, F. Coulon, and N. Poirier, Antagonist properties of monoclonal antibodies targeting human CD28: role of valency and the heavy-chain constant domain, MAbs, vol.5, issue.1, pp.47-55, 2013.

T. J. Dengler, G. Szabo, and B. Sido, Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation, Transplantation, vol.67, issue.3, pp.392-398, 1999.
DOI : 10.1097/00007890-199902150-00009

G. Suntharalingam, M. R. Perry, and S. Ward, Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412, N Engl J Med, vol.355, issue.10, pp.1018-1028, 2006.

F. Luhder, Y. Huang, and K. M. Dennehy, Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists, J Exp Med, vol.197, issue.8, pp.955-966, 2003.

M. S. Jang, F. Pan, and L. M. Erickson, A blocking anti-CD28-specific antibody induces long-term heart allograft survival by suppression of the PKC theta-JNK signal pathway, Transplantation, vol.85, issue.7, pp.1051-1055, 2008.

S. P. Raychaudhuri, S. Kundu-raychaudhuri, and K. Tamura,

. Fc-silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model, J Invest Dermatol, vol.128, issue.8, pp.1969-1976, 2008.

S. L. Shiao, J. M. Mcniff, and T. Masunaga, Immunomodulatory properties of FK734, a humanized anti-CD28 monoclonal antibody with agonistic and antagonistic activities, Transplantation, vol.83, issue.3, pp.304-313, 2007.

N. Poirier, C. Mary, and N. Dilek, Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody, Am J Transplant, vol.12, issue.10, pp.2630-2640, 2012.

N. Poirier, N. Dilek, and C. Mary, FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft, Am J Transplant, vol.15, issue.1, pp.88-100, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02148443

S. Ville, N. Poirier, and J. Branchereau, Anti-CD28 antibody and belatacept exert differential effects on mechanisms of renal allograft rejection, J Am Soc Nephrol, vol.27, issue.12, pp.3577-3588, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02150329

D. Liu, I. R. Badell, and M. L. Ford, Selective CD28 blockade attenuates CTLA-4-dependent CD8+ memory T cell effector function and prolongs graft survival, JCI Insight, vol.3, issue.1, p.96378, 2018.
DOI : 10.1172/jci.insight.96378
URL : http://insight.jci.org/articles/view/96378/files/pdf

B. K. Watkins, V. Tkachev, and S. N. Furlan, CD28 blockade controls T cell activation to prevent graft-versus-host disease in primates, J Clin Invest, vol.128, issue.9, pp.3991-4007, 2018.

N. Poirier, G. Blancho, and M. Hiance, First-in-human study in healthy subjects with FR104, a pegylated monoclonal antibody fragment antagonist of CD28, J Immunol, vol.197, issue.12, pp.4593-4602, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02150993

R. Shi, M. Honczarenko, and S. Zhang, Pharmacokinetic, pharmacodynamic, and safety profile of a novel anti-CD28 domain antibody antagonist in healthy subjects, J Clin Pharmacol, vol.57, issue.2, pp.161-172, 2017.

B. Dillinger, S. Ahmadi-erber, and K. Soukup, CD28 blockade ex vivo induces alloantigen-specific immune tolerance but preserves T-cell pathogen reactivity, Front Immunol, vol.8, p.1152, 2017.
DOI : 10.3389/fimmu.2017.01152
URL : https://hal.archives-ouvertes.fr/inserm-02154949

N. Poirier, G. Blancho, and B. Vanhove, CD28-specific immunomodulating antibodies: what 43
DOI : 10.1111/j.1600-6143.2012.04032.x
URL : https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-6143.2012.04032.x

N. Poirier, M. Chevalier, and C. Mary, Selective CD28 antagonist blunts memory immune responses and promotes long-term control of skin inflammation in nonhuman primates, J Immunol, vol.196, issue.1, pp.274-283, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02150299

N. Poirier, M. Chevalier, and C. Mary, Selective CD28 antagonist prevents Aldarainduced skin inflammation in non-human primates, Exp Dermatol, vol.25, issue.3, pp.233-234, 2016.
DOI : 10.1111/exd.12891
URL : https://hal.archives-ouvertes.fr/inserm-02150253

P. Malvezzi, T. Jouve, and L. Rostaing, Costimulation Blockade in kidney transplantation: an update, Transplantation, vol.100, issue.11, pp.2315-2323, 2016.

N. Kamar, D. Bello, A. Belliere, and J. , Calcineurin inhibitor-sparing regimens based on mycophenolic acid after kidney transplantation, Transpl Int, vol.28, issue.8, pp.928-937, 2015.
DOI : 10.1111/tri.12515

F. Haspot, C. Séveno, and A. S. Dugast, Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells, Am J
DOI : 10.1111/j.1600-6143.2005.01018.x